I Ask This Of You!

I have Parkinson's diseases and thought it would be nice to have a place where the contents of updated news is found in one place. That is why I began this blog.

I copy news articles pertaining to research, news and information for Parkinson's disease, Dementia, the Brain, Depression and Parkinson's with Dystonia. I also post about Fundraising for Parkinson's disease and events. I try to be up-to-date as possible.

I am not responsible for it's contents. I am just a copier of information searched on the computer. Please understand the copies are just that, copies and at times, I am unable to enlarge the wording or keep it uniformed as I wish.

This is for you to read and to always keep an open mind.

Please discuss this with your doctor, should you have any questions, or concerns.

Never do anything without talking to your doctor. I do not make any money from this website. I volunteer my time to help all of us to be informed. I will not accept any information about Herbal treatments curing Parkinson's, dementia and etc. It will go into Spam.

This is a free site for all with no advertisements.

Thank you for visiting!

Monday, July 24, 2017

Melbourne scientists discover brain iron may predict Alzheimer’s progression

July 24. 2017   Brigid O’Connell, Health reporter, Herald Sun

An specialised MRI scan, developed by the CSIRO, has been used to look for iron levels in the brain as a predictor Alzheimer’s disease.

MELBOURNE scientists have discovered scans for iron levels in the brain could identify people most at risk of Alzheimer’s.
In a major breakthrough in the fight against the devastating disease, scientists have found that those with significant brain plaque but low iron levels maintain cognitive performance over as much as six years.
But those with high iron levels — particularly in the hippocampus, the part of the brain involved in memory formation — progress faster to disease.
A team from the Florey ­Institute of Neuroscience and Mental Health and the CSIRO are behind the finding.
An iron chelator drug already on the market is showing promise at “mopping up” iron in the brains of Parkinson’s disease patients. The Florey team will now test if a twice-a-day dose taken over a year can slow Alzheimer’s progression.
If the trial is successful, Flor­ey Professor Ashley Bush said the 60-year-old GP health check could include a brain scan, followed by a PET scan if brain plaque is found, with medication to halt the disease before symptoms appear.

Flor­ey Professor Ashley Bush. Picture: Supplied

More than 413,000 Australians live with dementia symptoms, of which Alzheimer’s is the most common type.
Florey research fellow and lead author Dr Scott Ayton said: “For clinical trials to be effective, we want to treat people as early as possible.
“But until now we haven’t been able to identify who is going to decline.”
A third of adults aged over 65 have high levels of the plaque (beta-amyloid protein) in their brain, the equivalent to someone with advanced dementia. But many of these people are cognitively well and may never develop Alzheimer’s in their lifetime, showing there is more to the disease than just amyloid.
Hundreds of international clinical trials over the past 40 years focusing on these plaques have not resulted in any disease-modifying drug being approved for the clinic.
Prior studies by the Florey Institute of Neuroscience and Mental Health and others have suggested that iron levels in the brain — which have no connection to iron levels in the blood or iron consumed in the diet — could play a role in predicting who is at risk.
And working with the CSIRO, which developed a new method of measuring iron in the brain using a standard MRI machine, they recruited 117 participants and tested their cognitive function was tested every 18 months for six years.
The breakthrough findings were published today in the journal, Brain.
Prof Bush said: “For the first time, we will be able to assess someone’s risk of progressing into cognitive decline without needing to perform invasive or costly tests.”
The concept was first tested in a blinded experiment of 48 people published in 1991, which showed a first-generation iron chelator could half cognitive decline compared to placebo.
Dr Ayton said that study was never followed up as the international research world shifted its attention to the most logical target of beta-amyloid. But with more advanced scanning technology, he said they hoped to replicate the result.
If you are over 65 and have noticed your memory is declining, or you are newly diagnosed with dementia, register interest to be contacted when the study opens this year.

No comments:

Post a Comment